Covid-19 continues to befuddle Big Pharma as AbbVie axes PhI of an oral drug
In the fight against Covid-19, AbbVie’s approved products and investigational assets have run into multiple hurdles.
The latest is a Phase I axe, quietly revealed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.